SN
NTLA icon

Sittner & Nelson’s Intellia Therapeutics NTLA Stock Holding History

Sittner & Nelson’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$4.08K – 480
2023
Q2 		$4.08K Hold
100
– – ﹤0.01% 413
2023
Q1 		$3.73K Hold
100
– – ﹤0.01% 433
2022
Q4 		$3.49K Hold
100
– – ﹤0.01% 400
2022
Q3 		$6K Sell
100
-100
-50% -$6.2K ﹤0.01% 371
2022
Q2 		$10K Buy
200
+100
+100% +$5.08K 0.01% 362
2022
Q1 		$7K Hold
100
– – ﹤0.01% 365
2021
Q4 		$12K Buy
+100
New +$12.5K 0.01% 329

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sittner & Nelson's NTLA Position: Q3 2023 in Review

Sittner & Nelson sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 100 shares — an estimated $4.08K sold.

Sittner & Nelson first reported a position in NTLA in Q4 2021 and held it in 7 quarters. The position peaked at $12K in Q4 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • Sittner & Nelson reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Sittner & Nelson sold 100 Intellia Therapeutics shares in Q3 2023, an estimated $4.08K.
  • Sittner & Nelson first reported a position in Intellia Therapeutics in Q4 2021 and held it in 7 quarters.
  • Sittner & Nelson's Intellia Therapeutics position peaked at $12K in Q4 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Sittner & Nelson's 13F filing for Q3 2023, filed 13 Nov 2023.